Share
  • LinkedIn
  • Facebook
  • X
  • Threads

IP Whiteboard

Is your computer-implemented business method patentable? The Full Federal Court dismisses Research Affiliates’ appeal

11 November 2014

A unanimous Full Federal Court has held that a computer implemented method of creating an investment index is not patentable, on the basis that the substance of the claimed invention – an abstract idea or scheme – is itself not patentable subject matter and just because the claimed invention could be implemented using a computer does not make it patentable.

In Research Affiliates LLC v Commissioner of Patents [2014] FCAFC 150 (decision available here), the Full Court had to determine whether the use of a computer to implement an otherwise unpatentable business method was sufficient to render that method patentable. In finding that the use of a computer was not sufficient, the Full Court emphasised:

  1. the Court will focus on the substance of the invention when it is asked to assess whether a claimed invention is patentable.
  2. where a claimed invention is otherwise unpatentable, a computer must be important, if not integral, to the implementation of the claimed invention.

The Full Court’s decision confirms that use of a computer will not, of itself, transform an idea or method into a patentable invention.

IP Whiteboard’s James Ellsmore and Kim O’Connell have prepared an alert on the ramifications of the Full Federal Court’s decision, as well as providing a summary of the case. The alert is available here.

Share
  • LinkedIn
  • Facebook
  • X
  • Threads

More Posts From This Author

Generic supplier obtains substantial reduction in damages awarded against it

11 December 2018
Earlier this month, we reported on the Full Court’s decision in Generic Health v Bayer [2018] FCAFC 183, in which the Full Court clarified that when estimating or valuing a lost opportunity or assessing a hypothetical counterfactual for any scenario short of certainty, some discount must be made to reflect that less than certain position.  In doing so, the Full Court accepted that the trial judge, Justice Jagot, fell into error by not allowing for any such discount at first instance and proceeded to reduce the damages award by 2%.
Read on

Generic Health succeeds in invalidating patent for aripiprazole: Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 4) [2015] FCA 634

7 July 2015
Generic Health is perhaps a step closer to bringing its generic version of the antipsychotic drug aripiprazole to market in Australia after Justice Yates struck down one of Otsuka’s patents for the drug.  Although it’s unclear whether the path has been cleared for the launch of generic aripiprazole, Justice Yates’ decision – which found that key claims of the patent lacked novelty and were obvious – will be of interest to generic pharmaceutical companies faced with follow-on patents for known pharmaceutical compounds.
Read on